39757-31-8

Basic information

• Product Name: METHYL 4-(4-METHOXYPHENYL)-2,4-DIOXOBUTANOATE
• Synonyms: METHYL 4-(4-METHOXYPHENYL)-2,4-DIOXOBUTANOATE;Methyl 4-Methoxy-a,g-dioxo-benzenebutanoate;SALOR-INT L499250-1EA;AKOS B016257;AKOS BBS-00001167;ART-CHEM-BB B016257
• CAS NO: 39757-31-8
• Molecular Formula: C₁₂H₁₂O₅
• Molecular Weight: 236.22
• Mol File: 39757-31-8.mol

Chemical Properties

• Melting Point: 96-98
• Boiling Point: 396.4 °C at 760 mmHg
• Flash Point: 178 °C
• Appearance: /
• Density: 1.21 g/cm³
• Vapor Pressure: 1.71E-06mmHg at 25°C
• Refractive Index: 1.513
• CAS DataBase Reference: METHYL 4-(4-METHOXYPHENYL)-2,4-DIOXOBUTANOATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 4-(4-METHOXYPHENYL)-2,4-DIOXOBUTANOATE(39757-31-8)
• EPA Substance Registry System: METHYL 4-(4-METHOXYPHENYL)-2,4-DIOXOBUTANOATE(39757-31-8)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 39757-31-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
METHYL 4-(4-METHOXYPHENYL)-2,4-DIOXOBUTANOATE is used as a raw material for the synthesis of various pharmaceutical compounds. Its unique chemical structure allows it to be a versatile building block in the development of new drugs and medications.
Used in Agrochemical Industry:
In the agrochemical industry, METHYL 4-(4-METHOXYPHENYL)-2,4-DIOXOBUTANOATE is used as a starting material for the production of various agrochemicals, including pesticides and herbicides. Its chemical properties make it suitable for the development of effective and targeted agricultural products.
Used in Organic Compounds Synthesis:
METHYL 4-(4-METHOXYPHENYL)-2,4-DIOXOBUTANOATE is also used as a raw material in the synthesis of other organic compounds. Its reactivity and functional groups make it a valuable component in the creation of a wide range of organic molecules for various applications.
Safety Precautions:
It is important to handle METHYL 4-(4-METHOXYPHENYL)-2,4-DIOXOBUTANOATE with care, as it can be harmful if ingested, inhaled, or comes into contact with the skin or eyes. Proper safety measures, such as wearing protective clothing and using appropriate handling equipment, should be taken to minimize the risk of exposure.

InChI:InChI=1/C12H12O5/c1-16-9-5-3-8(4-6-9)10(13)7-11(14)12(15)17-2/h3-6H,7H2,1-2H3

Upstream product

• 553-90-2 Dimethyl oxalate 
• 100-06-1 1-(4-methoxyphenyl)ethanone 

Downstream Products

• 130421-38-4 4-(4-Methoxy-phenyl)-2,4-dioxo-N-pyridin-2-yl-butyramide 
• 425609-97-8 methyl 5-(4-methoxyphenyl)isoxazole-3-carboxylate 
• 33282-16-5 5-(4-methoxyphenyl)isoxazole-3-carboxylic acid 
• 192701-83-0 methyl 5-(4-methoxyphenyl)-1H-pyrazole-3-carboxylate 
• 27069-16-5 5-(4-methoxyphenyl)-1H-pyrazole-3-carboxylic acid 
• 1067181-28-5 5-cyclohexyl-3-hydroxy-1-(4-isoxazol-3-ylphenyl)-4-(4-methoxybenzoyl)-1,5-dihydropyrrol-2-one 

Relevant articles and documents

Design, synthesis, biological evaluation and in silico studies of pyrazole‐based nh2‐acyl oseltamivir analogues as potent neuraminidase inhibitors

Oseltamivir represents one of the most successful neuraminidase (NA) inhibitors in the current anti‐influenza therapy. The 150‐cavity of NA was identified as an additional binding pocket, and novel NA inhibitors have been designed to occupy the 150‐cavity

Novel N-Substituted oseltamivir derivatives as potent influenza neuraminidase inhibitors: Design, synthesis, biological evaluation, ADME prediction and molecular docking studies

The discovery of novel potent neuraminidase (NA) inhibitors remains an attractive approach for treating infectious diseases caused by influenza. In this study, we describe the design and synthesis of novel N-substituted oseltamivir derivatives for probing the 150-cavity which is nascent to the activity site of NA. NA inhibitory studies showed that new derivatives demonstrated the inhibitory activity with IC50 values at nM level against NA of a clinical influenza virus strain. Moreover, the in silico ADME predictions showed that the selected compounds had comparable properties with oseltamivir carboxylate, which demonstrated the druggablity of these derivatives. Furthermore, molecular docking studies showed that the most potent compound 6f and 10i could adopt different modes of binding interaction with NA, which may provide novel solutions for treating oseltamivir-resistant influenza. Based on the research results, we consider that compounds 6f and 10i have the potential for further studies as novel antiviral agents.

Non-peptide-based new class of platelet aggregation inhibitors: Design, synthesis, bioevaluation, SAR, and in silico studies

A series of 2-oxo-2-phenylethylidene linked 2-oxo-benzo[1,4]oxazine analogues 17a–x and 18a–o, incorporated with a variety of electron-withdrawing as well as electron-donating groups at ring A and ring C, were synthesized under greener conditions in excel

CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME

The present disclosure provides, in part, cyclic sulfamide compounds, and pharmaceutical compositions thereof, useful as modulators of Hepatitis B (HBV) core protein, and methods of treating Hepatitis B (HBV) infection.

Synthesis and mechanistic aspects of 2-anilinonicotinyl-pyrazolo[1,5-a]pyrimidine conjugates that regulate cell proliferation in MCF-7 cells via estrogen signaling

A series of anilinonicotinyl linked pyrazolo[1,5-a]pyrimidine conjugates (6a-x) were synthesized and evaluated for their antiproliferative activity. Some of these conjugates exhibited promising cytotoxic effects in the MCF-7 cell line and among these 6a a

Synthesis and anticancer activity of heteroaromatic linked 4β-amido podophyllotoxins as apoptotic inducing agents

A series of different heteroaromatic linked 4β-amidopodophyllotoxin conjugates (16a-i, 17a-i and 18a-d) were synthesized and evaluated for anticancer activity against five human cancer cell lines. Among the series, one of the compound 17g showed significant antiproliferative activity in A549 (lung cancer) cell line. Flow cytometric analysis showed that 17g arrested the cell cycle in the G2/M phase leading to caspase-3 dependent apoptotic cell death. Further, Hoechst 33258 staining and DNA fragmentation assay also suggests that 17g induces cell death by apoptosis.

Synthesis of pyrazolo[1,5-a]pyrimidine linked aminobenzothiazole conjugates as potential anticancer agents

A series of pyrazolo[1,5-a]pyrimidine linked 2-aminobenzothizole conjugates (6a-t) were synthesized and evaluated for their anticancer activity against five human cancer cell lines. Among them two compounds 6p and 6m showed significant anticancer activity with IC50 values ranging from 2.01 to 7.07 and 1.94-3.46 μM, respectively. Moreover, cell cycle arrest in G 2/M and reduction in Cdk1 expression level were observed upon treatment of these compounds and they also induced caspase-3 dependent apoptosis. This was further confirmed by staining as well as DNA fragmentation analysis.

Anthranilamide-Pyrazolo[1,5-a]pyrimidine Conjugates as p53 Activators in Cervical Cancer Cells

A library of new anthranilamide-pyrazolo[1,5-a]pyrimidine conjugates were designed, synthesized, and evaluated for their anticancer activity in cervical cancer cells such as HeLa and SiHa that possess low levels of p53. All 24 conjugates showed antiproliferative activity, while some of them exhibit significant cytotoxicity. In assays related to cell-cycle distribution, these conjugates induced G2/M arrest in HeLa cells and G1 cell-cycle arrest in SiHa cells. Immunocytochemistry assays revealed that these compounds cause nuclear translocation of p53, thereby indicating the activation of p53. In cervical cancer cells, the p53 protein is degraded by E6 oncoprotein. Immunoblot and RT-PCR analyses proved the presence of mitochondria-mediated apoptosis with involvement p53 target genes such as BAX, Bcl2, and p21 (CDKI). Moreover, these compounds increased the phosphorylated forms of p53 and provide signals for apoptosis induction. Interestingly, one of the conjugates, (2-phenyl-7-(3,4,5-trimethoxyphenyl)pyrazolo[1,5-a]pyrimidin-5-yl)(4-(2-(thiophen-2-ylmethylamino)benzoyl)piperazin-1-yl)methanone, is the most promising candidate in this series and has the potential to be taken up for further detailed studies.

Synthesis and SAR/3D-QSAR studies on the COX-2 inhibitory activity of 1,5-diarylpyrazoles to validate the modified pharmacophore

Diverse analogs of 1,5-diarylpyrazoles having 3-hydroxymethyl-4-sulfamoyl (SO2NH2)/methyl sulfonyl (SO2Me)-pheny group at N1 were synthesized and evaluated for their in vitro cyclooxygenase (COX-1/COX-2) inhibitory activity. The SAR study mainly involved the variations at positions C-3, C-5 and N1 of the pyrazole ring. Several small hydrophobic groups at/around position-4 of C-5 phenyl, viz. 3,4-dimethylphenyl analog 9, 3-methyl-4-methylsulfanylphenyl analog 14 and 2,3-dihydrobenzo[b] thiophenyl analog 17, exhibited impressive COX-2 inhibitory potency. In general, the sulfonamide analogues with a CHF2 at C-3 were found to be more potent than those having a CF3 group. The three dimensional quantitative structure activity relationship comprising comparative molecular field analysis (3D-QSAR-CoMFA) afforded the models with high predictivity which further validated the acceptance of hydroxymethyl (CH2OH) group in the hydrophilic pocket of the COX-2 enzyme.